Their recent study, published in PNAS (3), characterizes the mechanism of action of a smooth muscle
myosin inhibitor, CK - 2018571, that induces smooth muscle relaxation and can be used to treat diseases involving smooth muscle hypercontractility, such as asthma and chronic obstructive pulmonary disease.
Following this comment, we examined the dependency of ROCK /
myosin II in the LPA - mediated T cell motility in a collagen matrix and found that LPA - induced T cell motility was abrogated by the treatment of T - cells with blebbistatin or the Rho kinase
inhibitor Y27632.